DCAL Dishman Carbogen Amcis Q1 FY27 results (Apr–Jun 2026) and concall
Dishman Carbogen Amcis reported a soft Q1 FY27 with a 4.29% YoY revenue decline to INR 6,776 million and a significant drop in EBITDA to INR 600 million, primarily due to postponed orders and adverse forex movements. Despite the challenging quarter, the company highlighted operational successes including regulatory approvals, new product launches, and progress in tech transfers from Switzerland to India. Management remains optimistic about future growth, particularly in the Indian entity and the CDMO business, with plans for debt refinancing and a focus on top-line expansion to improve margins
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q1 FY27: revenue down 9.5%, net profit down 900.0% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 93 | 97 | 106 | 63 | 60 −35% | 40 −59% | 69 −35% | 57 −10% |
| EBITDA | 13 | 23 | 21 | 3 | 4 −69% | -4 −117% | 1 −95% | -12 −500% |
| Net profit | 14 | -13 | -7 | 3 | -14 −200% | -23 −77% | -4 +43% | -24 −900% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
